AGENCE NATIONALE DU

MEDICAMENT VETERINAIRE

FRENCH AGENCY FOR FOOD, ENVIRONNEMENTAL AND OCCUPATIONAL HEALTH SAFETY

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS

14 RUE CLAUDE BOURGELAT – PARC D'ACTIVITES DE LA GRANDE MARCHE JAVENE – CS 70611 – 35306 FOUGERES

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

ButorVet 10 mg/ml Solution for Injection for horses, dogs and cats

29/10/2024

Product name ButorVet 10 mg/ml	FR/V/0492/001/DC
Applicant CHANELLE PHARMACEUTICALS	DCP
Publicly available assessment report	

PRODUCT SUMMARY

EU procedure number	FR/V/0492/001/DC
Name, strength and pharmaceutical form	Butorphanol 10 mg/ml solution for injection
Applicant	CHANELLE PHARMACEUTICALS MANUFACTURING IDA INDUSTRIAL ESTATE DUBLIN ROAD, H62 FH90 LOUGHREA CO GALWAY IRELAND
Active substance(s)	Butorphanol
ATC vetcode	QN02AF01
Target species	horses, dogs and cats
Indication for use	HORSE As an analgesic: Relief of abdominal pain caused by colic of gastrointestinal origin. As a sedative (in combination) For sedation in combination with certain α2-adrenoceptor agonists (detomidine, romifidine). For therapeutic and diagnostic measures such as minor surgical procedures on the standing horse. DOG As an analgesic Relief of mild to moderate visceral pain and mild to moderate pain after soft tissue surgery. As a sedative (in combination) For deep sedation in combination with medetomidine. As a pre-anaesthetic Pre-anaesthetic use of the product has resulted in a dose related reduction in the dose of induction of anaesthetic agents. As an anaesthetic (in combination) As part of anaesthesia in combination with medetomidine and ketamine. CAT As an analgesic To alleviate moderate postoperative pain after soft tissue surgery and minor surgical procedures. As a sedative (in combination) For deep sedation in combination with medetomidine. As an anaesthetic (in combination) As part of anaesthesia in combination with medetomidine and ketamine.

PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

Product name ButorVet 10 mg/ml	FR/V/0492/001/DC
Applicant CHANELLE PHARMACEUTICALS	DCP
Publicly available assessment report	

SUMMARY OF ASSESSMENT

Legal basis of original application*	Article 18 - Generic application (Regulation (EU) 2019/6)
Reference product (RP)	Torbugesic 10 mg/mL solution for injection
Marketing authorisation holder	ZOETIS Belgium
MS where the RP is or has been authorised	Ireland
Marketing authorisation number EU procedure number	VPA 10387/079/001
Date of authorisation	01/10/2000
Date of completion of the original decentralised procedure	2/10/2024
Concerned Member States for original procedure	BE, DE, DK, EL, ES, FI, IE, IT, NL, NO, PT, SE
Withdrawn CMS during original <mutual recognition> <decentralised><subsequent recognition> procedure	/

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of referenceability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The VMP is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

2. QUALITY DOCUMENTATION (physicochemical, biological or microbiological information)

A. Product description

The VMP contains 10 mg/mL of butorphanol (equivalent to 14,58 mg of butorphanol tartrate) and the excipients benzethonium chloride, sodium citrate, citric acid monohydrate, sodium chloride and water for injections.

The container/closure system corresponds to amber glass vials of type I with chlorobutyl stopper and aluminium cap.

The choice of the formulation, and the presence of preservative are justified.

The VMP is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Description of the manufacturing method

The VMP is manufactured fully in accordance with the principles of good manufacturing practice at licensed manufacturing sites.

Process validation data on the VMP have been presented in accordance with the relevant European guidelines.

C. Production and control of starting materials

The active substance is butorphanol tartrate, an established active substance described in the pharmacopeia of a third country. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this VMP.

D. Control tests carried out on isolated intermediates during the manufacturing process

Not applicable.

E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification and their limits have been justified and are considered appropriate to adequately control the quality of the VMP.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability tests

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the VMP throughout its shelf life when stored under the approved conditions.

G. <Other information>

Not applicable.

3. SAFETY DOCUMENTATION (safety and residues tests)

A. Safety tests

Pharmacological studies

See part 4.

Toxicological studies

This application is being made according to the provisions of Article 18 - Generic application of Regulation 2019/6, no toxicological data were provided.

User safety

A user risk assessment has been provided. The proposed user warnings by the applicant are identical from those of the reference product. It is accepted that the candidate product has a similar user risk profile than the reference product and that no further assessment is required for the candidate product.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the VMP.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the VMP will be used to treat a small number of animals in a flock or herd

B. Residues documentation

Residue tests

The Applicant has not provided any residue depletion studies for this application.

Maximum Residue Limits

a. Active Substances

The active substance butorphanol is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010, as follows

BUTORPHANOL TARTRATE (ADI: 300 µg/kg)						
Marker residue	**Animal Species**	**MRL**	**Target Tissues**	**Other Provisions**	**Therapeutic Classification**	**Regulation**
Not applicable	Equidae	No MRL required	Not applicable	For intravenous administration only	No entry	37/2010 of 22.12.2009

b. Excipients

The MRL status of excipients listed in section 2 of the SPC is indicated in the following table

Excipient	**MRL status**	
Benzethonium chloride	Out of scope list	"For use as a preservative at a total dose no greater than 4 mg per animal for intramuscular and subcutaneous administration and without limit for other administration routes."
Citric acid monohydrate	Food additives	
Sodium Citrate	Food additives	
Sodium Chloride	Table 1, all species, no MRL required, No ADI	
Water for injections	Out of scope list	

Withdrawal Periods

Withdrawal times for the reference product are also applied to the product proposed in this application, as follows:

Horses:
- Meat and offal: zero days
- Milk: zero days

4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and bioequivalence with a reference VMP has been demonstrated, efficacy studies are not required.

The efficacy claims for this VMP are equivalent to those of the reference VMP.

A. Pre-Clinical Studies

Pharmacology

Given the legal basis of this application and the claim of bioequivalence between candidate and reference products, the omission of pharmacodynamics/pharmacokinetics data is considered acceptable, as this information may be extrapolated from the reference product.

The bioequivalence was demonstrated according to the section 7.1 of the bioequivalence GL EMA/CVMP/016/2000-Rev4*).

Tolerance in the target species of animals

It is accepted that the target animal safety profile of the test product will be the same as that of the reference product. The text in sections 3.6 and 3.10 of the proposed SPC is in line with the text of the reference product.
The product literature accurately reflects the type and incidence of adverse effects, which might be expected.

B. Clinical trials

No clinical trials were performed.

5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.